PC
Polar Capital Portfolio holdings
AUM
$13.5B
This Quarter Return
+15.77%
1 Year Return
+55.85%
3 Year Return
+125.38%
5 Year Return
+259.12%
10 Year Return
–
AUM
$13.5B
AUM Growth
+$13.5B
(+16%)
Cap. Flow
+$1.08B
Cap. Flow
% of AUM
8.03%
Top 10 Holdings %
Top 10 Hldgs %
31.74%
Holding
335
New
58
Increased
111
Reduced
91
Closed
41
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
$159M |
| 2 |
Johnson & Johnson
JNJ
|
$156M |
| 3 |
Chegg
CHGG
|
$85M |
| 4 |
Medtronic
MDT
|
$74.6M |
| 5 |
Humana
HUM
|
$71.3M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$135M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$123M |
| 3 |
Ciena
CIEN
|
$99.1M |
| 4 |
Advanced Micro Devices
AMD
|
$87.5M |
| 5 |
Zoom
ZM
|
$74.1M |
Sector Composition
| 1 | Technology | 35.5% |
| 2 | Healthcare | 19.85% |
| 3 | Financials | 14.53% |
| 4 | Communication Services | 13.92% |
| 5 | Consumer Discretionary | 8.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Citigroup
C
$175B
| $21.1M | 0.16% |
489,347
+78,253
| +19% | +$3.37M |
|
127
US Foods
USFD
$17.4B
| $19.9M | 0.15% |
893,370
-338,658
| -27% | -$7.53M |
|
128
Altria Group
MO
$112B
| $19.6M | 0.15% |
507,831
-62,982
| -11% | -$2.43M |
|
129
Y-mAbs Therapeutics
YMAB
$390M
| $19.4M | 0.14% |
506,083
| – | – |
|
|
GBT
130
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $19.3M | 0.14% |
350,000
+175,000
| +100% | +$9.65M |
|
131
AtriCure
ATRC
$1.73B
| $19.1M | 0.14% |
478,119
+94,994
| +25% | +$3.79M |
|
132
BioMarin Pharmaceuticals
BMRN
$11.3B
| $19M | 0.14% |
250,000
-255,000
| -50% | -$19.4M |
|
133
Eli Lilly
LLY
$661B
| $18.9M | 0.14% |
+128,000
| New | +$18.9M |
|
134
Celldex Therapeutics
CLDX
$1.57B
| $18.5M | 0.14% |
+1,250,000
| New | +$18.5M |
|
|
CHNGU
135
DELISTED
Change Healthcare Inc. Tangible Equity Units
CHNGU
| $17.9M | 0.13% |
335,000
| – | – |
|
|
XLRN
136
DELISTED
Acceleron Pharma Inc.
XLRN
| $17.8M | 0.13% |
157,762
+59,684
| +61% | +$6.72M |
|
|
137
UnitedHealth
UNH
$279B
| $17.7M | 0.13% |
56,672
-432,727
| -88% | -$135M |
|
138
Summit Therapeutics
SMMT
$17.5B
| $17.2M | 0.13% |
5,000,000
+500,000
| +11% | +$1.72M |
|
139
IQVIA
IQV
$31.4B
| $16.6M | 0.12% |
105,293
-316,440
| -75% | -$49.9M |
|
140
Dollar General
DG
$24.1B
| $16.4M | 0.12% |
+78,150
| New | +$16.4M |
|
141
Oracle
ORCL
$628B
| $16.2M | 0.12% |
+270,980
| New | +$16.2M |
|
142
Surgery Partners
SGRY
$2.89B
| $16.1M | 0.12% |
+736,792
| New | +$16.1M |
|
143
Kulicke & Soffa
KLIC
$1.9B
| $16.1M | 0.12% |
719,850
+134,943
| +23% | +$3.02M |
|
144
TE Connectivity
TEL
$60.9B
| $15.8M | 0.12% |
161,711
+45,869
| +40% | +$4.48M |
|
145
Becton Dickinson
BDX
$54.3B
| $15.6M | 0.12% |
67,052
-1,300
| -2% | -$303K |
|
146
Atlassian
TEAM
$44.8B
| $15.4M | 0.11% |
84,752
+46,759
| +123% | +$8.5M |
|
147
Kura Oncology
KURA
$732M
| $15.3M | 0.11% |
+500,000
| New | +$15.3M |
|
|
AVDL
148
Avadel Pharmaceuticals
AVDL
$1.42B
| $15M | 0.11% |
2,978,915
| – | – |
|
149
Aflac
AFL
$57.1B
| $14.9M | 0.11% |
410,000
| – | – |
|
150
ProAssurance
PRA
$1.22B
| $14.9M | 0.11% |
950,000
+250,000
| +36% | +$3.91M |
|